Skip to main content

Advertisement

SpringerLink
Log in

Secondary Acute Myeloid Leukemias Arising From Philadelphia Chromosome Negative Myeloproliferative Neoplasms: Pathogenesis, Risk Factors, and Therapeutic Strategies

  • Acute Myeloid Leukemias (R Stone, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

The classic Philadelphia chromosome negative myeloproliferative neoplasms including primary myelofibrosis, polycythemia vera, and essential thrombocythemia are associated with a variable propensity for transformation into acute myeloid leukemia. Leukemic transformation in these disorders, so called MPN-blast phase, is uniformly associated with a poor prognosis. In recent years, there has been an increasing understanding of the molecular complexity underlying Philadelphia chromosome negative myeloproliferative neoplasms (Ph− MPNs), and this has spurred efforts to investigate the molecular risk factors associated with clinical outcome in these disorders, including the risk of leukemic transformation. At the same time, there is an ongoing and significant need for new approaches which have the potential to change the natural history of these disorders. This review will focus on the risk factors associated with the development of MPN in blast phase (MPN-BP) including clinical and molecular risk factors, current treatment strategies, and emerging investigational approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Abdulkarim K, Girodon F, Johansson P, et al. AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol. 2009;82:106–11.

    Article  PubMed  Google Scholar 

  2. Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85:124–7.

    Article  CAS  PubMed  Google Scholar 

  3. Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood. 2008;112:1628–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  CAS  PubMed  Google Scholar 

  6. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–13. quiz 2615. This large study involving more than 1500 patients demonstrates that patients with primary myelofibrosis who are negative for CALR, MPL, and JAK2 have an inferior outcome and an increased risk of leukemic transformation. The study also outlines the natural history of Ph-MPNs, demonstrates a superior survival in ET compared with PV, and underscores the fact that even in the genomic era, clinical phenotype is still relevant with regard to predicting the natural history of these disorders.

  7. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–901.

    Article  CAS  PubMed  Google Scholar 

  8. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–8.

    Article  CAS  PubMed  Google Scholar 

  9. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116:2857–8.

    Article  CAS  PubMed  Google Scholar 

  10. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27:5587–93.

    Article  PubMed  Google Scholar 

  11. Passamonti F, Rumi E, Elena C, et al. Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol. 2010;150:719–21.

    Article  PubMed  Google Scholar 

  12. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664–70.

    Article  CAS  PubMed  Google Scholar 

  13. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392–7.

    Article  PubMed  Google Scholar 

  14. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105:973–7.

    Article  CAS  PubMed  Google Scholar 

  15. Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer. 2005;104:1032–6.

    Article  PubMed  Google Scholar 

  16. Rumi E, Harutyunyan A, Elena C, et al. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol. 2011;86:974–9.

    Article  CAS  PubMed  Google Scholar 

  17. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90. This study demonstrates for the first time the occurrence of mutations in CALR in the majority of JAK2 mutation and MPL mutation-negative MPNs. In addition, the favorable prognostic impact conferred by the presence of this mutation was also demonstrated.

    Article  CAS  PubMed  Google Scholar 

  18. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405. This study demonstrates for the first time the occurrence of mutations in CALR in the majority of JAK2 mutation and MPL mutation-negative MPNs.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861–9. This comprehensive analysis of 10 recurrently mutated candidate genes in two large multi institutional cohorts of patients with PMF demonstrated that mutations in five genes including ASXL1, EZH2, SRSF2, and IDH1/2 were associated with poor clinical outcome, including increased risk of leukemic transformation in primary myelofibrosis.

    Article  CAS  PubMed  Google Scholar 

  20. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220–8.

    Article  CAS  PubMed  Google Scholar 

  21. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006;108:3548–55.

    Article  CAS  PubMed  Google Scholar 

  22. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110:375–9.

    Article  CAS  PubMed  Google Scholar 

  23. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362:369–70.

    Article  CAS  PubMed  Google Scholar 

  24. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70:447–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119:4480–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A. 2014;111:E5401–10. This study illustrates the important role of TP53 mutations in facilitating leukemic transformation in Ph− MPN. In addition a murine model of JAK2V617F mutant, TP53-deficient AML is developed, providing an in vivo validation of the role of TP53 mutations in the pathogenesis of MPN-BP. This murine model is also a valuable tool for investigating novel therapies and approaches in MPN-BP.

  27. Harutyunyan A, Klampfl T, Cazzola M, et al. p53 lesions in leukemic transformation. N Engl J Med. 2011;364:488–90.

    Article  CAS  PubMed  Google Scholar 

  28. Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood. 2013;121:2725–33. This retrospective study highlights the potential role of allogeneic stem cell transplantation in modifying the natural history of MPN-BP in the context of relatively uniform treatment strategy in which patients were offered induction therapy based on their level of fitness.

    Article  CAS  PubMed  Google Scholar 

  29. Cahu X, Chevallier P, Clavert A, et al. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2014;49:756–60.

    Article  CAS  PubMed  Google Scholar 

  30. Robin M, Giannotti F, Deconinck E, et al. Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant. 2014;20:1841–6.

    Article  PubMed  Google Scholar 

  31. Mascarenhas J, Navada S, Malone A, et al. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res. 2010;34:1246–9.

    Article  PubMed  Google Scholar 

  32. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116:3735–42.

    Article  CAS  PubMed  Google Scholar 

  33. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.

    Article  CAS  PubMed  Google Scholar 

  34. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.

    Article  CAS  PubMed  Google Scholar 

  35. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35. This study demonstrates the superiority of ruxolitinib to the best available therapy in the context of second-line therapy for PV.

    Article  CAS  PubMed  Google Scholar 

  36. Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119:4614–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Odenike O. Beyond JAK inhibitor therapy in myelofibrosis. Hematol Am Soc Hematol Educ Program. 2013;2013:545–52.

    Article  Google Scholar 

  38. Mascarenhas J, Heaney ML, Najfeld V, et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012;36:1500–4.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Michael Tallarico declares no potential conflict of interest.

Dr. Olatoyosi Odenike reports grants paid to her institution for clinical research from Eisai; Lily, Novartis, NS-Pharma, S*Bio, Incyte, Gilead, MEI-Pharma, Topotarget, Astex, Celgene, Geron, Sunesis, Spectrum, Sanofi; personal fees for advisory board participation from Sunesis, Spectrum, Sanofi, Incyte and Algeta.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 S. Maryland Ave., MC 2115, Chicago, IL, 60637, USA

    Michael Tallarico & Olatoyosi Odenike

  2. The Comprehensive Cancer Center, The University of Chicago, Chicago, IL, USA

    Olatoyosi Odenike

Authors
  1. Michael Tallarico
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olatoyosi Odenike
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olatoyosi Odenike.

Additional information

This article is part of the Topical Collection on Acute Myeloid Leukemias

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tallarico, M., Odenike, O. Secondary Acute Myeloid Leukemias Arising From Philadelphia Chromosome Negative Myeloproliferative Neoplasms: Pathogenesis, Risk Factors, and Therapeutic Strategies. Curr Hematol Malig Rep 10, 112–117 (2015). https://doi.org/10.1007/s11899-015-0259-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-015-0259-0

Keywords

Search

Navigation